Dermatologic Adverse Events Related to the PI3Kα Inhibitor Alpelisib (BYL719) in Patients with Breast Cancer

PURPOSE: Rash develops in approximately 50% of patients receiving alpelisib for breast cancer, often requiring dose modifications. Here, we describe the clinicopathologic, laboratory, and management characteristics of alpelisib-related dermatologic adverse events (dAEs). METHODS: A single center ret...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Wang, Diana G., Barrios, Dulce M., Blinder, Victoria S., Bromberg, Jacqueline F., Drullinsky, Pamela R., Funt, Samuel A., Jhaveri, Komal L., Lake, Diana E., Lyons, Tomas, Modi, Shanu, Razavi, Pedram, Sidel, Michelle, Traina, Tiffany A., Vahdat, Linda T., Lacouture, Mario E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7398571/
https://ncbi.nlm.nih.gov/pubmed/32613539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05726-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados